Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSVpreF + BNT162b2
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RSVpreF + BNT162b2 is a combination of two vaccines: RSVpreF, a bivalent prefusion F protein-based vaccine targeting respiratory syncytial virus (RSV) subgroups A and B, and BNT162b2, an mRNA-based COVID-19 vaccine encoding the spike protein of SARS-CoV-2. The combination is being studied for concomitant or admixed administration to protect older adults against both RSV and COVID-19. Clinical studies in adults aged 65 years or older have shown that the combined or coadministered vaccines are safe, well tolerated, and elicit noninferior immune responses compared to each component given alone. This approach aims to improve vaccination rates by simplifying immunization schedules for multiple respiratory pathogens[1][2][5].
- Brand names
- Abrysvo
- Other names
- bivalent respiratory syncytial virus prefusion F vaccine + bivalent mRNA COVID-19 vaccinecombined RSV and COVID-19 vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on RSVpreF + BNT162b2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSVpreF + BNT162b2.